2020
Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym
Longo D, Shoda L, Howell B, Coric V, Berman R, Qureshi I. Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym. Toxicological Sciences 2020, 175: 292-300. PMID: 32040174, PMCID: PMC7253195, DOI: 10.1093/toxsci/kfaa019.Peer-Reviewed Original ResearchConceptsOral tabletsALT elevationLiver toxicityClinical dataFirst-pass liver metabolismLiver function test parametersFirst-pass hepatic metabolismLiver toxicity riskAlanine transaminase levelsRelative risk reductionLower overall doseAmyotrophic lateral sclerosisALT levelsTransaminase levelsLiver exposureSublingual formulationHepatic metabolismLateral sclerosisRiluzoleLiver metabolismULNInterindividual variabilityOverall doseHepatotoxicity potentialOxidative stress
2019
RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS
Kluger H, Forsyth P, Khushalani N, Eroglu Z, Sznol M, Tran T, Jilaveanu L, Cohen J, Hegde U, Wei W, Mahajan A, Goldberg S, Chiang V, Weiss S. RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS. Neuro-Oncology 2019, 21: vi220-vi220. PMCID: PMC6847787, DOI: 10.1093/neuonc/noz175.919.Peer-Reviewed Original ResearchVEGF inhibitorsPrimary endpointPD-1/PD-L1Anti-PD-1 activityGrade 3 ALT elevationPre-specified primary endpointPhase 2 studyPhase 2 trialUnconfirmed PRALT elevationDiverticular perforationMetS patientsCerebral edemaPD-L1Wound dehiscencePembroToxicity profileEdemaFurther studiesPromising activityEndpointBRAFmtPembrolizumabMucositisULN
2018
Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy
Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch A, Oh W, Galsky M, Ahmad J, Odin J. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. Journal Of Clinical Gastroenterology And Hepatology 2018, 2 PMID: 30637414, PMCID: PMC6327955, DOI: 10.21767/2575-7733.1000047.Peer-Reviewed Original ResearchLiver testsCumulative incidenceLiver injuryRenal cell carcinomaReal-world studyElevated LTChemotherapy initiationGenitourinary malignanciesRetrospective reviewCell carcinomaChemotherapeutic agentsAffected patientsChemotherapyClinical significanceClinical trialsTreatment planningPatientsCancer treatmentUndergoing ChemotherapySignificance of drugsULNLT resultsDILITreatmentLiver
2005
Liver enzyme values in injection drug users with chronic hepatitis C
Mehta S, Netski D, Sulkowski M, Strathdee S, Vlahov D, Thomas D. Liver enzyme values in injection drug users with chronic hepatitis C. Digestive And Liver Disease 2005, 37: 674-680. PMID: 15951255, DOI: 10.1016/j.dld.2005.03.009.Peer-Reviewed Original ResearchConceptsHepatitis C virusHepatitis C virus-infected personsAcute viral hepatitisLiver enzyme valuesVirus-infected personsC virusAminotransferase levelsViral hepatitisAlanine aminotransferaseAlanine aminotransferase/aspartate aminotransferase ratioChronic hepatitis C virus (HCV) infectionEnzyme valuesHepatitis C virus infectionAspartate aminotransferase ratioC virus infectionChronic hepatitis CHigher alanine aminotransferaseInjection drug usersHepatitis CAminotransferase ratioSerologic testingLiver enzymesULNVirus infectionDrug users
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply